Teva Pharmaceuticals (TEVA) - Tuesday, Jan 16, 2024

176 Views16 Apr 2024 20:01
Syndicated
SUMMARY
  • Teva Pharmaceuticals and Viatris Inc are leading global generic pharmaceutical manufacturers with diverse drug portfolios.
  • Both companies are currently undervalued and are anticipated to see substantial shareholder returns in 2024.
  • Despite challenges in the US generic drug industry, Teva and Viatris are poised for significant upside potential in the near future.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Value Investors Club
External reports (aggregated public sources)
Value Investors Club
Equity Bottom-UpEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x